PluriPLUR +1.19%25 Current Ratio is 0.33 as of Mar. 2026, which is 94% below its 10-year median of 5.24. GuruFocus rates PLUR with a GF Score™ of 25/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, Pluri ranks worse than 93.44% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pluri's current ratio for the quarter that ended in Mar. 2026 was 0.33.
Pluri has a current ratio of 0.33. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Pluri has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Pluri's Current Ratio or its related term are showing as below:
PLUR'
s Current Ratio Range Over the Past 10 Years
Min: 0.33 Med: 5.24 Max: 9.91
Current: 0.33
During the past 13 years, Pluri's highest Current Ratio was 9.91. The lowest was 0.33. And the median was 5.24.
PLUR's Current Ratio is ranked worse than 93.44% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs PLUR: 0.33
Pluri (NAS:PLUR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pluri Current Ratio Related Terms
Pluri Current Ratio Historical Data
* Premium members only.
The historical data trend for Pluri's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pluri's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pluri's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri (PLUR) has a Current Ratio of 0.33 as of Mar. 2026. This is 94% below median its historical median of 5.24. Over the past decade, Pluri's Current Ratio has ranged from 0.33 to 9.91. According to the industry distribution chart, Pluri ranks #1324 out of 1417 companies in the Biotechnology industry, placing it in the top 93.4%.
Is Pluri's Current Ratio too high?
Pluri's current Current Ratio of 0.33 is 94% below median its 10-year median of 5.24. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 9.91. The Biotechnology industry median Current Ratio is 3.89. Pluri's value of 0.33 is 91.5% below this industry median. Based on the distribution chart, Pluri ranks #1324 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pluri has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's Current Ratio compare to VTGN and PTN?
According to the Biotechnology industry distribution chart, Pluri ranks #1324 out of 1417 companies for Current Ratio. This places Pluri in the lower half of its industry. The industry median Current Ratio is 3.89. Pluri's value of 0.33 is 91.5% below this benchmark. Historically, Pluri's own Current Ratio has ranged from 0.33 to 9.91 over the past decade. While the company's 10-year median is 5.24 vs. the industry median of 3.89, Pluri has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pluri's current Current Ratio of 0.33 is 91.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pluri's current Current Ratio is 0.33, which is 94% below median its own 10-year median of 5.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $2.12 — trading 67.2% below its estimated fair value. The current Current Ratio is 0.33, which is 94% below median its 10-year median of 5.24 and 91.5% below the Biotechnology industry median of 3.89. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Pluri (PLUR), the current Current Ratio is 0.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (PLUR) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of $2.12 is trading 67.2% below its estimated GF Value™ of $6.46.
GuruFocus considers Pluri to be Possible Value Trap.
Key valuation signals for PLUR:
Current Ratio: 0.33 (94% below median its 10-year median of 5.24)
GF Value™: $6.46 vs. price of $2.12 (67.2% below fair value)
Industry Position: 91.5% below the Biotechnology median (#1324 of 1417)
No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score
Get the complete analysis for PLUR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLUR has been successfully added to your 
